Gilead Sciences Inc. Advances HIV Prevention Efforts with European Medicines Agency Validation of Lenacapavir Application
Reuters
Jul 09, 2025
<a href="https://laohu8.com/S/GILD">Gilead</a> Sciences Inc. Advances HIV Prevention Efforts with European Medicines Agency Validation of Lenacapavir Application
Gilead Sciences Inc. has announced a strategic partnership with the Global Fund to Fight AIDS, Tuberculosis and Malaria to accelerate access to lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for HIV prevention in primarily low- and lower-middle-income countries. This agreement will enable Gilead to supply the medicine to up to two million people over three years at no profit, while awaiting the availability of licensed generic versions. The European Medicines Agency has validated Gilead's application for lenacapavir under the EU-M4all procedure, which could expedite regulatory reviews in resource-limited countries. Gilead is actively collaborating with global aid organizations to ensure timely distribution and is pursuing strategies to support access in middle-income countries not covered by this agreement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250708231509) on July 09, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.